• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一项由研究者发起的关于丙酸氯倍他索和他扎罗汀聚合物乳剂治疗掌跖银屑病的试验。

An Investigator-Initiated Trial of a Polymeric Emulsion of Halobetasol Propionate and Tazarotene in the Treatment of Palmoplantar Psoriasis.

作者信息

Yousif Jenna, Babalola Folawiyo, Campbell Caroline, Gottlieb Alice, Vargas Jessica, Mitchell Krystal

出版信息

J Drugs Dermatol. 2023 Feb 1;22(2):223-225. doi: 10.36849/JDD.7067.

DOI:10.36849/JDD.7067
PMID:36745373
Abstract

UNLABELLED

Copy: Palmoplantar psoriasis is a chronic, difficult-to-treat localized variant of psoriasis that affects the palms and soles, significantly affecting patient's quality of life.

OBJECTIVE

To evaluate the synergistic effect of a fixed-combination topical lotion composed of halobetasol propionate 0.01% and tazarotene 0.045% in the treatment of palmoplantar psoriasis.

METHODS

This was an open-label investigator-initiated trial involving 21 patients with moderate-to-severe palmoplantar plaque-type psoriasis who underwent treatment with halobetasol propionate 0.01% and tazarotene 0.045%. Subjects were assessed for disease severity using the palmoplantar Physician Global Assessment and the mean difference over time was compared using the Wilcoxon signed-rank test.

RESULTS

5 patients (24%) achieved a palmoplantar Physician Global Assessment of 0 or 1 after week 24 or last observation carried forward. The mean palmoplantar Physician Global Assessment significantly decreased from baseline (3.57) to week 24/last observation carried forward (2.38) (P<0.001).

DISCUSSION

Halobetasol propionate 0.01% and tazarotene 0.045% lotion demonstrated efficacy in adult patients with moderate-to-severe palmoplantar plaque-type psoriasis through significant improvement in palmoplantar Physician Global Assessment. The complementary mechanisms of action of the corticosteroid and tazarotene may be of benefit compared to monotherapeutic agents. J Drugs Dermatol. 2023;22(2): 223-225. doi:10.36849/JDD.7067.

摘要

未标注

复制:掌跖银屑病是银屑病的一种慢性、难以治疗的局限性变体,会影响手掌和脚底,严重影响患者的生活质量。

目的

评估由0.01%丙酸氯倍他索和0.045%他扎罗汀组成的固定复方外用洗剂治疗掌跖银屑病的协同作用。

方法

这是一项开放标签、由研究者发起的试验,纳入21例中度至重度掌跖斑块型银屑病患者,接受0.01%丙酸氯倍他索和0.045%他扎罗汀治疗。使用掌跖医师整体评估法评估疾病严重程度,并使用Wilcoxon符号秩检验比较随时间的平均差异。

结果

5例患者(24%)在第24周或末次观察时实现掌跖医师整体评估为0或1。掌跖医师整体评估的平均值从基线时的(3.57)显著降至第24周/末次观察时的(2.38)(P<0.001)。

讨论

0.01%丙酸氯倍他索和0.045%他扎罗汀洗剂在中度至重度掌跖斑块型银屑病成年患者中显示出疗效,掌跖医师整体评估有显著改善。与单一治疗药物相比,皮质类固醇和他扎罗汀的互补作用机制可能有益。《药物皮肤病学杂志》。2023年;22(2): 223 - 225。doi:10.36849/JDD.7067。

相似文献

1
An Investigator-Initiated Trial of a Polymeric Emulsion of Halobetasol Propionate and Tazarotene in the Treatment of Palmoplantar Psoriasis.一项由研究者发起的关于丙酸氯倍他索和他扎罗汀聚合物乳剂治疗掌跖银屑病的试验。
J Drugs Dermatol. 2023 Feb 1;22(2):223-225. doi: 10.36849/JDD.7067.
2
Efficacy, Safety, and Tolerability of a Halobetasol 0.01% /Tazarotene 0.045% Fixed Combination in the Treatment of Severe Localized Plaque Psoriasis: Post Hoc Analysis of Two Phase III Randomized Controlled Trials.0.01% 卤倍他索/0.045% 他扎罗汀固定组合治疗重度局限性斑块状银屑病的疗效、安全性及耐受性:两项III期随机对照试验的事后分析
J Drugs Dermatol. 2019 Oct 1;18(10):1012-1018.
3
Assessing the Synergistic Effect of a Fixed Combination Halobetasol Propionate 0.01% and Tazarotene 0.045% Lotion in Moderate-to-Severe Plaque Psoriasis.评估0.01%丙酸氯倍他索与0.045%他扎罗汀固定复方洗剂治疗中重度斑块状银屑病的协同效应。
J Drugs Dermatol. 2019 Mar 1;18(3):279-284..
4
An Open-Label Pilot Study to Investigate Safety and Efficacy of Fixed Combination Tazarotene 0.045% and Halobetasol Propionate 0.01% Lotion for the Treatment of Scalp Psoriasis.一项开放性、单臂试验研究,旨在评估他扎罗汀 0.045%与卤倍他索丙酸 0.01%联合洗剂治疗头皮银屑病的安全性和疗效。
J Drugs Dermatol. 2021 Nov 1;20(11):1191-1194. doi: 10.36849/jdd.0102.
5
A Phase 2, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of a Halobetasol/Tazarotene Fixed Combination in the Treatment of Plaque Psoriasis.一项评估卤米松/他扎罗汀固定组合治疗斑块状银屑病安全性和有效性的2期、多中心、双盲、随机、赋形剂对照临床研究。
J Drugs Dermatol. 2017 Mar 1;16(3):197-204.
6
Halobetasol and Tazarotene: Further Defining the Role of a Unique Fixed Combination Topical Lotion in Moderate-to-Severe Plaque Psoriasis.卤倍他索和他扎罗汀:进一步明确一种独特的固定复方外用洗剂在中重度斑块状银屑病中的作用
J Drugs Dermatol. 2018 Dec 1;17(12):1290-1296.
7
Fixed-Combination Halobetasol Propionate/Tazarotene Lotion for Psoriasis in Patients With 3%-5% Affected Body Surface Area.用于 3%-5%体表面积受累的银屑病患者的固定剂量复方卤倍他索/他扎罗汀乳膏。
J Drugs Dermatol. 2021 Aug 1;20(8):829-836. doi: 10.36849/JDD.6217.
8
Halobetasol 0.01%/Tazarotene 0.045% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: Maintenance of Therapeutic Effect After Cessation of Therapy.0.01%卤倍他索/0.045%他扎罗汀洗剂治疗中度至重度斑块状银屑病:治疗停止后的疗效维持
J Drugs Dermatol. 2019 Aug 1;18(8):815-820.
9
Halobetasol 0.01%/Tazarotene 0.045% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: Maintenance of Therapeutic Effect After Cessation of Therapy.0.01%卤倍他索/0.045%他扎罗汀洗剂治疗中度至重度斑块状银屑病:治疗停止后的疗效维持
J Drugs Dermatol. 2018 Jul 1;17(7):723-726.
10
Fixed Combination Halobetasol Propionate and Tazarotene Lotion for Plaque Psoriasis.卤米松/他扎罗汀复方制剂洗剂治疗斑块状银屑病。
Skin Therapy Lett. 2021 Nov;26(6):1-3.